News
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression (PPD) into the indication's standard of care.
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...
Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...
Having witnessed a 90%-plus stock price slide during recent years, Sage Therapeutics’ leadership must decide whether now is the right time to accept a buyout offer. Biogen has offered to ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback